T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin.
about
Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.A temporal examination of calcium signaling in cancer- from tumorigenesis, to immune evasion, and metastasis.CAV3.1 knockdown suppresses cell proliferation, migration and invasion of prostate cancer cells by inhibiting AKT
P2860
T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin.
description
2016 nî lūn-bûn
@nan
2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin.
@ast
T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin.
@en
type
label
T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin.
@ast
T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin.
@en
prefLabel
T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin.
@ast
T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin.
@en
P2093
P2860
P1476
T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin.
@en
P2093
Barbara Dziegielewska
Eli V Casarez
Jaroslaw Dziegielewski
Jill K Slack-Davis
Lloyd S Gray
Wesley Z Yang
P2860
P304
P356
10.1158/1535-7163.MCT-15-0456
P577
2016-02-01T00:00:00Z